News & Media

Colonis Pharma (part of the Clinigen group of companies), and a leader in developing and commercialising value added medicines, has announced the first and exclusive licence and distribution agreement with Hyloris Pharmaceuticals for XTRAZA(™)
(tranexamic acid), a proprietary oral rinse designed for use in dental procedures.

We have successfully implemented the Windsor Framework requirements for human medicines packaging and labelling across all of our products. This achievement ensures that all Colonis UK human medicinal products placed on the UK market from 1st January 2025 have clearly legible ‘UK Only’ text on their packaging. This is to show that they are for sale in the UK and not in EU countries. 

Following our recent partnership with Movianto, they have created a case study to showcase exactly how working together has helped to further develop our processes and enhance the delivery of value-added medicines for patients across the UK and beyond.

Recognising the value in value added medicines is key to our vision of transforming the future of healthcare. With this in mind, we are pleased to announce that we’ve been accepted as a member of the Medicines for Europe Value Added Medicines Group.

Colonis Pharma, is delighted to announce its new collaboration with Movianto, a leading supply chain solutions partner, to optimize its

Colonis Pharma, a leading pharmaceutical company focused on innovative value-added medicines, has announced the strengthening of its longstanding partnership with

Suzie Stratford, Alliance and Business Development Manager and Narendra Patel, New Product Business Development Manager are attending euroPLX Lisbon on

As an innovative company with great ambition to develop value-added medicines and treatment options that benefit patients, we are incredibly proud to be accepted as a full member of the British Generic Manufacturers Association (BGMA).